Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy (oHCM) has been treated using its drug mavacamten at Ruijin Hospital’s Hainan branch. Mavacamten, the world’s first cardiac myosin inhibitor, received approval from the Hainan Medical Products Administration for special entry into the Hainan Bo’ao Medical Pilot Zone.
Marketed as Camzyos, mavacamten is a first-in-class cardiac myosin inhibitor that reversibly binds to myosin to address the excess contractility and impaired relaxation that are hallmarks of HCM. The drug received its initial approval in the US in April 2022 for the treatment of class II-III oHCM and has since gained approvals in significant markets across Asia, including South Korea, Macau, and Singapore. The formation of excessive actin-myosin bridges and the dysregulation of the hyperrelaxation state are key mechanistic features of HCM. Mavacamten modulates the number of myosin heads capable of entering the “bound actin” state, reducing the likelihood of dynamic generation and residual formation of transverse bridges during systolic and diastolic phases, respectively. This shifts the overall myosin population into an energy-efficient hyper-relaxed state. In patients with HCM, inhibiting myosin with mavacamten can alleviate left ventricular outflow tract (LVOT) obstruction and enhance cardiac filling pressure.- Flcube.com
